Related Experiment Video
Updated: Jun 26, 2026
09:01
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Chronic myeloid leukemia in Asia
Wing Y Au1, Priscilla B Caguioa2, Charles Chuah3
1Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, Hong Kong.
International Journal of Hematology
|December 23, 2008
Summary
Chronic myeloid leukemia (CML) in Asia affects younger patients. Imatinib mesylate (IM) is the primary treatment, improving survival but facing resistance, necessitating newer tyrosine kinase inhibitors.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Chronic myeloid leukemia (CML) incidence in Asia is lower than in Western countries but affects a younger demographic.
- Imatinib mesylate (IM) has replaced older treatments like busulfan, hydroxyurea, and interferon-alpha as the standard first-line therapy for CML.
- The introduction of IM has significantly reduced the need for hematopoietic stem cell transplantation (HSCT).
Purpose of the Study:
- To review available data on Chronic myeloid leukemia (CML) epidemiology and treatment in various Asian countries.
- To assess the efficacy and challenges of imatinib mesylate (IM) treatment in the Asian CML population.
- To highlight the emergence of imatinib resistance and the need for novel therapies in Asia.
Main Methods:
- Review of existing epidemiological and clinical data on CML in China, Hong Kong, India, the Philippines, Singapore, South Korea, Taiwan, and Thailand.
- Analysis of treatment outcomes with imatinib mesylate (IM), including response rates and adverse events.
- Examination of the prevalence and implications of imatinib resistance in Asian CML patients.
Main Results:
- Imatinib mesylate (IM) achieves complete cytogenetic response in 60-90% of newly diagnosed CML patients and up to 10% in blastic phase.
- Most patients tolerate the standard 400 mg IM dose, though adverse events like cytopenia occur.
- Imatinib resistance is emerging in Asian CML patients, similar to Western populations.
Conclusions:
- Imatinib mesylate (IM) has dramatically improved survival for CML patients in Asia, often obviating the need for HSCT.
- Access to IM is widespread through patient assistance programs, enabling prolonged survival.
- The development of resistance to IM necessitates the availability of newer tyrosine kinase inhibitors (TKIs) like dasatinib and nilotinib in Asia.
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
01:27Disorders of Leukocytes
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...